findmyKOL
Clinical trialNCT06066138RecruitingPhase 1Interventional

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

SponsorNational Cancer Institute (NCI)Enrollment30Locally Advanced Alveolar Soft Part SarcomaLocally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaLocally Advanced Non Small Cell Lung CancerLocally Advanced Small Cell Lung CancerMetastatic Alveolar Soft Part Sarcoma+4 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • National Institutes of Health Clinical Center

    Bethesda, Maryland, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Nov 2025
Primary completion
31 Jan 2027
Completion
31 Jan 2028
Last update posted
10 Jul 2026
Registered enrollment
30
Registry id
NCT06066138

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.